Scientists say that blocking a protein called DLK could help protect against neurodegeneration of demyelinated nerve cells in ...

Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment ... sclerosis, also known as scleroderma, is a rare autoimmune disease that causes ...

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis ...

Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic ...

The PIPE financing included participation from new and existing healthcare specialist investors ... diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

Scientists at UMC Utrecht have developed a new technology to efficiently isolate a specific subset of gut bacteria from fecal ...

Completed dosing of 115 participants in a bioavailability and bioequivalence (BA/BE) clinical trial in Australia for IHL-42X, an investigational treatment for obstructive sleep apnea in July 2024.

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completion NVG-300 preclinical test-of-concept studies ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...